CorMedix is a bio-pharmaceutical company that produces DefenCath, an antimicrobial catheter lock solution containing ...

For all cases of CRBSI, if the CVC is no longer needed for management of the patient, it should be removed. Empiric antimicrobial therapy regimens for suspected CRBSI should be developed based on ...

On Thursday, 05 June 2025, CorMedix Inc. (NASDAQ:CRMD) presented at the Jefferies Global Healthcare Conference 2025, outlining its strategic initiatives and financial achievements. The company ...

Results: Significant differences were observed in the incidence of CRBSI (P Conclusion: The combination of CHG antimicrobial dressing and cluster nursing demonstrated superior outcomes in artificial ...

The global CRBSI treatment market is on a significant growth trajectory, projected to experience a compound annual growth rate (CAGR) of 5.4% between 2025 and 2035. This growth is being propelled by ...

A study in patients with solid tumors found that CRBSI is significantly linked to mortality in patients with PICCs, whereas CRT and CRLC are not significant risk factors.

Mino-Lok is an antibiotic lock solution aimed at salvaging catheters in patients with central line-associated bloodstream infections (CLABSI) or catheter-related bloodstream infections (CRBSI).

Central venous catheter (CVC) tip cultures are useful in the assessment of a patient with a potential catheter-related bloodstream infection (CRBSI). However, these results can be misleading ...

Both CLABSIs and CRBSIs were associated with increased risk of all-cause mortality and longer hospital stays, particularly among patients who required ICU admission.

The fight against Catheter-Related Bloodstream Infections (CRBSI) is gaining ground, fueled by a growing market for effective treatments. According to Future Market Insights (FMI), a leading market ...